An acquisition of a U.S./UK pharmaceutical company by a company with China ties is being reviewed by the Committee on Foreign Investment in the United States (CFIUS) and its UK counterpart.

You don't have access to this post on China Trade Monitor at the moment, but if you upgrade your account you'll be able to see the whole thing, as well as all the other posts in the archive! Subscribing only takes a few seconds and will give you immediate access.

This post is for subscribers only

Subscribe now